Information Center

  • Move News
  • Move FAQ
  • inquiry

News News

News
Samyang Biopharmaceuticals Corporation’s Bendalid Inj. Signaling Successful Market Entry Scrap Facebook Scrap Twitter Print
Writer administrator Hits 3701 2021.04.05

 

- Seeks to enter large hospitals in just 1 month since its launch, and is under review by the DC in 15 hospitals
- Ensures safety without injecting nitrogen gas with its independently developed method using drug substances from Germany
- Seeks to expand abroad as the only generic launched in both 25 mg and 100 mg bottles

 

Blood cancer drug Bendalid Inj. successfully localized by Samyang Biopharmaceuticals Corporation

 

Samyang Biopharmaceuticals Corporation’s blood cancer drug Bendalid Inj. (ingredient: bendamustine) is signaling successful market entry as it seeks to advance into large hospitals in just 1 month since its launch.

 

Samyang Biopharmaceuticals Corporation (CEO Eom Tae-ung) announced on Mar. 31 that Bendalid Inj. is under review by the drug committee (DC) of 15 university hospitals. The DC procedure intends to determine whether a drug can be prescribed in a hospital.

 

Bendalid Inj. is a generic drug of Eisai Korea’s Symbenda Inj. and has indications for combination therapy with the target anti-cancer drug rituximab in follicular lymphoma, a malignant tumor in lymphatic tissue, chronic lymphocytic leukemia, a type of blood cancer, and multiple myeloma.

 

Samyang Biopharmaceuticals Corporation has successfully localized bendamustine, for which the country has solely relied on imports, and launched the first generic in both 25 mg and 100 mg bottles on Mar. 1. Except for the original drug’s company, Samyang Biopharmaceuticals Corporation is the only company that launches bendamustine in both doses of 25 mg and 100 mg.

 

In particular, Samyang Biopharmaceuticals Corporation’s Bendalid Inj. ensures safety without injecting nitrogen gas with its independently developed low-temperature manufacturing method and uses drug substances from Germany to improve reliability in quality.

 

An official from Samyang Biopharmaceuticals Corporation said, “Samyang Biopharmaceuticals Corporation is the only company in Korea that can produce both 25 mg and 100 mg bottles of bendamustine. As Pharmaceutical Plant in Daejeon, which produces Bendalid Inj., has been certified for European and Japanese GMP, we will expand abroad.”

 

Meanwhile, Samyang Biopharmaceuticals Corporation began to expand its cytotoxic anti-cancer injection factory last year to boost its global contract development and manufacturing organization (CDMO) business. Currently, a factory whose expected total capacity covers 5 million vials including 4 million liquid injection vials and 1 million lyophilisation vials is being expanded in Daejeon.

News Previous article, News Next article, and title
이전글 Samyang Group Sudang Foundation Held the 30th Sudang Awards 2021.05.11
다음글 Samyang Group’s Yangyoung Foundation and Sudang Foundation Provide Scholarships for 2021 2021.03.03
List

inquiry